Skip to content

Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01149577
Enrollment
25
Registered
2010-06-23
Start date
2007-08-31
Completion date
2009-04-30
Last updated
2010-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, Sleep

Keywords

Olanzapine, Schizophrenia, Polysomnography, Slow wave sleep

Brief summary

Acute and sub-chronic administration of olanzapine has shown a favourable effect on the sleep disturbances in previously medicated schizophrenia patients with predominantly negative symptoms. The present study will be carried out to clarify the effect of olanzapine on polysomnographic profiles of schizophrenia patients in an acute phase of illness after controlling for the drug effects.

Detailed description

Twenty schizophrenia patients (11 drug naïve and 9 drug free) will be studied over a period of six weeks of olanzapine treatment. Patients will be assessed at the baseline on BPRS, PANSS, CDSS and UKU side effect rating scales and a baseline 40 channels polysomnography will be done. After the initial assessment, patients will put on olanzapine treatment, in flexible dosages based on clinical response, for a period of six weeks when a final assessment on clinical rating scales and polysomnography will be done. The sleep data will be scored manually for staging based on Rechtschaffen and Kales criteria.

Interventions

DRUGOlanzapine

06 weeks treatment with Olanzapine in a flexible dosage schedule.

Sponsors

Central Institute of Psychiatry, Ranchi, India
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Male patients fulfilling International Classification of Diseases-10 Diagnostic Criteria for Research for schizophrenia 2. Aged 18-50 Yrs 3. Drug naïve or drug free (not receiving any psychotropic medication for the past 4 months) 4. Consenting

Exclusion criteria

1. Any comorbid psychiatric illness 2. Significant medical or neurological illness 3. History of significant head injury, epilepsy 4. Substance use in the past 4 months excluding nicotine and caffeine 5. Presence of a primary sleep disorder

Design outcomes

Primary

MeasureTime frameDescription
Sleep EEG06 weeksChanges in Sleep EEG parameters like Total sleep time, total sleep period, sleep efficiency, sleep latency, stage shifts, stage 1 shifts, stage 1 parameters, stage 2 parameters, stage 3 parameters, stage 4 parameters, rapid eye movement (REM) parameters.

Secondary

MeasureTime frameDescription
Psychopathology06 weeksChanges in psychopathological scores as measured by Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS).

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026